Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Figure 1

Cumulative percentages (confidence intervals) of retreatment after discontinuation of infliximab in patients treated for ankylosing spondylitis. Retreatment depended on the duration of response to the initial treatment. Of the 42 patients, 10 had to be retreated within 12 weeks after discontinuation of infliximab infusions, 37 within 24 weeks, and 38 within 36 weeks. By week 48, 1 of the 42 patients had not needed retreatment and 41 were again receiving infliximab.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us